Adding Epoetin Alfa to Intense Dose-Dense Adjuvant Chemotherapy for Breast Cancer: Randomized Clinical Trial

BACKGROUND: The AGO-ETC trial compared 5-year relapse-free survival of intense dose-dense (IDD) sequential chemotherapy with epirubicin (E), paclitaxel (T), and cyclophosphamide (C) (IDD-ETC) every 2 weeks vs conventional scheduled epirubicin/cyclophosphamide followed by paclitaxel (EC→T) (every 3 w...

Descripción completa

Detalles Bibliográficos
Autores principales: Moebus, Volker, Jackisch, Christian, Schneeweiss, Andreas, Huober, Jens, Lueck, Hans-Joachim, du Bois, Andreas, Thomssen, Christoph, Kurbacher, Christian, Kuhn, Walther, Nitz, Ulrike, Runnebaum, Ingo B., Hinke, Axel, Kreienberg, Rolf, Untch, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3714019/
https://www.ncbi.nlm.nih.gov/pubmed/23860204
http://dx.doi.org/10.1093/jnci/djt145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3714019/
https://www.ncbi.nlm.nih.gov/pubmed/23860204
http://dx.doi.org/10.1093/jnci/djt145

Ejemplares similares